CNS Pharmaceuticals Inc
CNSP5.510USD
+0.100+1.85%
Market hours （ET）Quotes delayed by 15 min
3.17MMarket Cap
0.01P/E TTM
More Details of CNS Pharmaceuticals Inc Company
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS Pharmaceuticals Inc Info
Ticker SymbolCNSP
Company nameCNS Pharmaceuticals Inc
IPO dateNov 08, 2019
CEOClimaco (John Michael)
Number of employees4
Security typeOrdinary Share
Fiscal year-endNov 08
Address2100 West Loop S Ste 900
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77027-3522
Phone18009469185
Websitehttps://cnspharma.com/
Ticker SymbolCNSP
IPO dateNov 08, 2019
CEOClimaco (John Michael)
Company Executives of CNS Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-3.00%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+1.00%
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Independent Director
Independent Director
--
-1.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Bettina M. Cockroft, M.D.
Dr. Bettina M. Cockroft, M.D.
Independent Director
Independent Director
--
-1.00%
Ms. Amy Mahery
Ms. Amy Mahery
Independent Director
Independent Director
--
-1.00%
Name
Name/Position
Position
Shareholding
Change
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
5.00
-3.00%
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
2.00
+1.00%
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Independent Director
Independent Director
--
-1.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
UBS Financial Services, Inc.
0.03%
Other
92.29%
Shareholders
Shareholders
Proportion
Stonepine Capital Management, LLC
5.19%
DRW Securities, LLC
2.27%
Cortice Biosciences, Inc.
0.15%
UBS Switzerland AG
0.07%
UBS Financial Services, Inc.
0.03%
Other
92.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.19%
Investment Advisor
2.30%
Corporation
0.15%
Bank and Trust
0.07%
Other
92.28%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
34
57.74K
7.40%
+32.22K
2025Q3
34
25.52K
7.99%
-17.21K
2025Q2
30
42.73K
1.82%
+37.38K
2025Q1
30
5.15K
1.78%
+786.00
2024Q4
28
5.89K
1.26%
+3.16K
2024Q3
24
2.73K
0.48%
+2.49K
2024Q2
21
240.00
1.54%
+206.00
2024Q1
23
34.00
3.95%
+20.00
2023Q4
20
11.00
4.00%
+6.00
2023Q3
22
5.00
7.14%
--
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
DRW Securities, LLC
14.05K
2.27%
+14.05K
--
Sep 30, 2025
Cortice Biosciences, Inc.
956.00
0.17%
+956.00
--
Jul 30, 2024
UBS Switzerland AG
416.00
0.07%
+416.00
--
Sep 30, 2025
UBS Financial Services, Inc.
2.67K
0.47%
+677.00
+33.88%
Jun 30, 2025
Morgan Stanley & Co. LLC
28.00
0%
+28.00
--
Sep 30, 2025
Barrett & Company, Inc.
8.00
0%
--
--
Jun 30, 2025
Climaco (John Michael)
8.00
0%
--
--
May 09, 2025
BofA Global Research (US)
4.00
0%
+3.00
+300.00%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
Date
Ex-dividend Date
Type
Ratio
Jul 18, 2025
Merger
12→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Feb 19, 2025
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Jun 03, 2024
Merger
50→1
Nov 28, 2022
Merger
30→1
View more
